SCHEMBL8306489

SCHEMBL8306489

CC(=NO)c1ccc2ccccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.70
GFER P55789 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
CYP2C19 P33261 2/20 0.57
CYP2D6 P10635 1/20 0.57
MAPT P10636 5/20 0.53
RAB9A P51151 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CES2 O00748 1/20 0.52
CES1 P23141 1/20 0.52
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
NPC1 O15118 2/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8485793 1.00 CASP3 (0.70) CASP3GFERSENP8SENP7SENP6
SCHEMBL10041971 1.00 CASP3 (0.70) CASP3GFERSENP8SENP7SENP6
SCHEMBL29510116 1.00 CASP3 (0.70) CASP3GFERSENP8SENP7SENP6
SCHEMBL28252406 0.94 CASP3 (0.68) CASP3GFERSENP8SENP7SENP6
SCHEMBL1758758 0.82 GFER (1.00) CASP3GFERSENP8SENP7SENP6
SCHEMBL1758756 0.82 GFER (1.00) CASP3GFERSENP8SENP7SENP6
SCHEMBL18138431 0.82 CES2 (0.55) CASP3GFERSENP8SENP7SENP6
SCHEMBL18138433 0.82 CES2 (0.55) CASP3GFERSENP8SENP7SENP6
SCHEMBL20677082 0.79 KDM4E (0.58) CASP3GFERSENP8SENP7SENP6
SCHEMBL9633241 0.79 PPARG (0.48) CASP3GFERSENP8SENP7SENP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106146350-A A kind of new method of synthesizing amino methylcarbamoyl oximino ester derivant 华南理工大学 2016-11-23 CN claimed
CN-101704758-B Method for preparing 2-naphthylamine UNIV BEIJING NORMAL 2013-06-05 CN claimed
CN-101704758-A Method for preparing 2-naphthylamine UNIV BEIJING NORMAL 2010-05-12 CN claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 US disclosed
EP-4242213-A1 BORONIC ACID COMPOUND Lg Chem, Ltd. (KR) 2023-09-13 EP disclosed
WO-2022123530-A1 BORONIC ACID COMPOUND 주식회사 엘지화학 2022-06-16 WO disclosed
CN-107522635-B N-cyclopropyl nitrone derivatives and preparation method thereof 东北师范大学 2020-02-14 CN disclosed
CN-107011201-B A kind of preparation method of amide 南京工业大学 2019-11-22 CN disclosed
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2019-01-08 US disclosed
EP-2927218-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2018-07-04 EP disclosed
EP-0810997-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1997-12-10 EP disclosed
CN-1143639-A Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-02-26 CN disclosed
WO-1996026191-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-08-29 WO disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed
EP-0588785-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1994-03-30 EP disclosed
US-5185363-A Administering for treatment of inflammatory diseases ABBOTT LABORATORIES (US) 1993-02-09 US disclosed
EP-0588785-A4 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS. ABBOTT LAB (US) 1991-12-30 EP disclosed
WO-1990012008-A1 UREA BASED LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1990-10-18 WO disclosed
EP-0292699-A2 Urea based lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 CASP3 2821/4885GFER 4172/4885SENP8 409/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 CASP3 1789/4885GFER 3805/4885SENP8 534/4885
US-10174033-B2 N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof ADORA2A, ADORA3, ADORA1 CASP3 843/4885GFER 3565/4885SENP8 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.